Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENICILLAMINE vs BAFIERTAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.
BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.
Wilson's disease,Cystinuria,Rheumatoid arthritis,Lead poisoning,Mercury poisoning,Arsenic poisoning
FDA-approved: Treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.,Off-label: None widely documented.
250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.
120 mg orally once daily.
Terminal half-life: 1.5–2 hours for penicillamine; after chronic dosing, a slower phase (t1/2 ~40 hours) appears due to tissue binding. Clinical context: Dosing interval typically 6–8 hours; accumulation may occur in renal impairment.
Approximately 12 hours (range 8–15 hours); permits twice-daily dosing in multiple sclerosis.
Hepatic metabolism to S-methyl-penicillamine and penicillamine disulfide; also undergoes renal excretion.
BAFIERTAM is a prodrug that is rapidly metabolized by esterases in the gastrointestinal tract, blood, and tissues to monomethyl fumarate. Monomethyl fumarate is further metabolized via the tricarboxylic acid (TCA) cycle, with no significant involvement of cytochrome P450 enzymes.
Renal: ~80% as unchanged drug and metabolites; fecal: ~20% (via biliary elimination).
Primarily via renal excretion as unchanged drug (approximately 80% of the dose); minimal biliary/fecal elimination (<5%).
~80% bound to plasma proteins, primarily albumin.
30–40% bound to plasma proteins, primarily albumin.
Vd: 0.1–0.2 L/kg; indicates distribution mainly in extracellular fluid and limited tissue penetration, though accumulates in skin and connective tissue.
Approximately 0.5–0.7 L/kg; indicates distribution into total body water with limited tissue binding.
Oral: 40–70% (variable due to food and metal ions).
Oral: Approximately 50% (due to first-pass metabolism); administer with food to reduce GI irritation.
Cr Cl >=50 m L/min: no adjustment; Cr Cl 30-49 m L/min: reduce dose by 50%; Cr Cl 10-29 m L/min: reduce dose by 75%; Cr Cl <10 m L/min: avoid use.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
No specific adjustments recommended; use with caution in severe hepatic impairment.
Use with caution in hepatic impairment; reduce dose to 60 mg once daily in Child-Pugh Class B or C.
For Wilson disease: 250 mg/m²/day orally in divided doses; for cystinuria: 30 mg/kg/day in divided doses; for rheumatoid arthritis: 2.5-5 mg/kg/day, titrated slowly.
Not established in pediatric patients.
Initiate at low end of dosing range; monitor renal function closely; increased risk of hematologic and autoimmune adverse effects.
No specific dose adjustment; use with caution due to age-related decline in renal function.
None explicitly issued by FDA.
No black box warning.
Bone marrow suppression (leukopenia, thrombocytopenia, aplastic anemia), proteinuria/nephrotic syndrome, autoimmune reactions (myasthenia gravis, Goodpasture's syndrome, lupus-like syndrome), severe skin reactions (toxic epidermal necrolysis), hepatotoxicity, cross-allergenicity with penicillin. Requires monitoring of CBC, urinalysis, liver function.
Lymphopenia: May cause reduction in lymphocyte counts; monitor complete blood count before and periodically during treatment.,Hypersensitivity reactions: Anaphylaxis and angioedema may occur; discontinue if severe.,Progressive multifocal leukoencephalopathy (PML): Reported in patients with prolonged lymphopenia; consider holding therapy if lymphocyte counts drop below 0.2 x 10^9/L.,Hepatic injury: Elevations of liver enzymes have been reported; monitor in patients with pre-existing liver disease.,Flushing and gastrointestinal events: Common; may be managed by taking with food or using aspirin.
History of aplastic anemia or agranulocytosis, severe renal insufficiency, pregnancy (especially first trimester), breastfeeding, hypersensitivity to penicillamine or penicillin.
Known hypersensitivity to BAFIERTAM, monomethyl fumarate, or any excipient.,Concomitant use with dimethyl fumarate or other fumaric acid esters.
Avoid high-protein meals and dairy products around dosing; they decrease penicillamine absorption. Separate intake from iron supplements, antacids, and zinc by at least 2 hours. For cystinuria, maintain high fluid intake and possibly restrict sodium and methionine-rich foods (e.g., meats, dairy) as part of therapy.
Administer with food to reduce flushing and gastrointestinal adverse effects. Avoid alcohol consumption during treatment as it may exacerbate flushing. No specific dietary restrictions are required.
First trimester: Known teratogen; associated with cutis laxa, congenital hip dislocation, and other skeletal abnormalities. Contraindicated unless treatment for Wilson disease or cystinuria. Second/third trimesters: Risk of fetal connective tissue defects; avoid unless essential.
BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic potential.
Excreted in breast milk; M/P ratio approximately 0.1. Low concentrations are present; however, due to potential adverse effects (e.g., rash, bone marrow suppression), caution is advised. Consider monitoring infant for rash or blood dyscrasias.
No data on presence in human milk. M/P ratio unknown. Risk of infant exposure cannot be excluded. Discontinue breastfeeding or drug, considering importance to mother.
No specific dose adjustment is recommended based on pharmacokinetic changes alone; however, due to potential teratogenicity, use only when necessary. Therapeutic drug monitoring may be considered to ensure efficacy without excessive toxicity.
No dose adjustment data; contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately. Pharmacokinetic changes unknown but drug should not be used.
Penicillamine is a chelating agent used for Wilson disease, cystinuria, and rheumatoid arthritis. Monitor for bone marrow suppression, proteinuria, and autoimmune reactions. Administer on an empty stomach (1 hour before or 2 hours after meals). Avoid concurrent use with gold, antimalarials, or immunosuppressants due to increased toxicity. Discontinue if rash, fever, or lymphadenopathy develop.
BAFIERTAM (monomethyl fumarate) is a prodrug of monomethyl fumarate, indicated for relapsing forms of multiple sclerosis. Administer with food to reduce flushing and gastrointestinal adverse effects. Titrate as per recommended schedule to improve tolerability. Monitor complete blood count, liver function tests, and renal function at baseline and periodically. Flushing may be reduced by taking with food or using non-enteric coated aspirin (325 mg) 30 minutes prior. Avoid concurrent use with dimethyl fumarate or other fumaric acid esters.
Take penicillamine on an empty stomach, at least 1 hour before or 2 hours after meals.,Avoid taking with milk, antacids, or iron supplements as they reduce absorption.,Report any unexplained bruising, bleeding, sore throat, or fever immediately.,Watch for signs of proteinuria (foamy urine) or hematuria (blood in urine).,Do not stop abruptly; dose tapering is required.,Use effective contraception; penicillamine can cause fetal harm.
Take BAFIERTAM exactly as prescribed, usually twice daily with food.,Flushing and gastrointestinal upset are common but may decrease over time; taking with food and gradual dose titration helps.,Do not crush, chew, or open capsules; swallow whole.,Report any signs of infection, unusual bruising or bleeding, or severe abdominal pain to your healthcare provider.,Avoid consuming alcohol, as it may increase flushing risk.,If you miss a dose, take it as soon as you remember unless it is near the time of the next dose; do not double up.,Inform all healthcare providers that you are taking BAFIERTAM.
"Almasilate, an aluminum-containing antacid, can adsorb penicillamine in the gastrointestinal tract, forming an insoluble complex that reduces penicillamine absorption. This leads to decreased serum concentrations of penicillamine, potentially diminishing its therapeutic effect in diseases such as rheumatoid arthritis or Wilson's disease. Clinically, this interaction may result in loss of disease control or require dose adjustments."
"Calcium carbonate, a common antacid and calcium supplement, chelates with penicillamine in the gastrointestinal tract, forming an insoluble complex that reduces penicillamine absorption. This interaction significantly decreases the bioavailability and serum concentration of penicillamine, potentially compromising its therapeutic efficacy in treating conditions such as rheumatoid arthritis or Wilson's disease. Clinical outcomes may include loss of disease control or increased disease activity, particularly if the drugs are taken concomitantly."
"Concomitant administration of penicillamine and teriflunomide may significantly increase the serum concentration of teriflunomide, primarily due to penicillamine's inhibition of the organic anion transporter 3 (OAT3)-mediated renal elimination of teriflunomide. Elevated teriflunomide levels heighten the risk of dose-dependent adverse effects, including hepatotoxicity, peripheral neuropathy, and immunosuppression. This interaction warrants careful monitoring and potential dose adjustment to avoid toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENICILLAMINE vs BAFIERTAM, answered by our medical review team.
PENICILLAMINE is a Chelating Agent that works by Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.. BAFIERTAM is a Iron Chelating Agent that works by BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENICILLAMINE and BAFIERTAM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENICILLAMINE is: 250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.. The standard adult dose of BAFIERTAM is: 120 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENICILLAMINE and BAFIERTAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENICILLAMINE is classified as Category C. First trimester: Known teratogen; associated with cutis laxa, congenital hip dislocation, and other skeletal abnormalities. Contraindicated unless treatment for Wilson disease or c. BAFIERTAM is classified as Category C. BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.